SOPHiA GENETICS SA (SOPH)
3.38
-0.05 (-1.46%)
At close: Jan 14, 2025, 3:59 PM
3.50
3.55%
After-hours Jan 14, 2025, 07:24 PM EST
undefined% (undefined)
| Bid | 1.36 |
| Market Cap | 220.97M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.09 |
| PE Ratio (ttm) | -3.1 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 5.4 |
| Volume | 24,675 |
| Avg. Volume (20D) | 27,662 |
| Open | 3.45 |
| Previous Close | 3.43 |
| Day's Range | 3.31 - 3.45 |
| 52-Week Range | 2.70 - 7.37 |
| Beta | undefined |
About SOPH
SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Su...
Sector Healthcare
IPO Date Jul 23, 2021
Employees 430
Stock Exchange NASDAQ
Ticker Symbol SOPH
Website https://www.sophiagenetics.com
Analyst Forecast
According to 3 analyst ratings, the average rating for SOPH stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 107.10% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
SOPHiA GENETICS SA is scheduled to release its earnings on Mar 4, 2025,
before market opens.
Analysts project revenue of $18.10M, reflecting a 6.17% YoY growth and earnings per share of -0.23, making a -37.84% decrease YoY.
Analysts project revenue of $18.10M, reflecting a 6.17% YoY growth and earnings per share of -0.23, making a -37.84% decrease YoY.
2 months ago ·
Source
-9.33%
Sophia Genetics shares are trading lower. The stoc...
Unlock content with
Pro Subscription
5 months ago ·
Source
-2.17%
SOPHiA GENETICS shares are trading lower after the company reported mixed Q2 financial results and issued FY24 revenue guidance below estimates.
